NCT03023176 is a Phase 4 clinical trial of Fluzone® standard IIV3 in Influenza, sponsored by Stanford University.

Who is sponsoring NCT03023176?

NCT03023176 is sponsored by Stanford University.

What drugs are being tested in NCT03023176?

Interventions in NCT03023176: Fluzone® standard IIV3, Fluzone® standard IIV3 Pediatric Dose.

Is NCT03023176 still recruiting?

NCT03023176 is currently completed. Last updated 3 April 2017.

Are results published for NCT03023176?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-04-03 · How we verify

NCT03023176

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 5, 2013

Completed Phase 4 Results posted Last updated 3 April 2017

What this trial tests

Phase 4 trial testing Fluzone® standard IIV3 in Influenza in 20 participants. Completed in 1 November 2013.

Timeline

1 September 2013

Primary endpoint
1 November 2013

1 November 2013

Quick facts

Lead sponsor	Stanford University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	20
Start date	1 September 2013
Primary completion	1 November 2013
Estimated completion	1 November 2013

Drugs / interventions tested

Fluzone® standard IIV3 — full drug profile →
Fluzone® standard IIV3 Pediatric Dose — full drug profile →

Conditions studied

Influenza — all drugs for Influenza →

Sponsor

Stanford University

Who can join

Adults 1 to 8, any sex, with Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants Who Received Influenza Vaccine
Time frame: Day 0 to 32

Sponsor's own description

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging.
Sayed N, Huang Y, Nguyen K, Krejciova-Rajaniemi Z, et al · · 2021 · cited 413× · PMID 34888528 · DOI 10.1038/s43587-021-00082-y
The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system.
Tomic A, Tomic I, Dekker CL, Maecker HT, et al · · 2019 · cited 12× · PMID 31636302 · DOI 10.1038/s41597-019-0213-4

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03023176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 3 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03023176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing